4 active not recruiting, 2 completed, 2 unknown, 1 not yet recruiting. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Active not recruiting 4, Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
Follow Neuroendocrine Neoplasm: new trials by email Literature Review of Neuroendocrine Neoplasm trials Research Report on Neuroendocrine Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of IM-1340 in Participants With Advanced Cancer IM-1340 - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Immunome, Inc. | 200 | 2026-11-01 | 2026-10-22 |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors CRN09682 - SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors | Phase 1 / Phase 2 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 150 | 2025-11-26 | 2026-10-13 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens [225Ac]Ac-DOTATATE - Neuroendocrine Neoplasm | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 36 | 2024-09-29 | 2025-06-26 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Neuroendocrine Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-07-22 | 2026-06-15 |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography - Bladder Carcinoma, Cervical Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 26 | 2020-08-27 | 2026-02-05 |
| A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors ZSP1602 - Basal Cell Carcinoma, Medulloblastoma | Phase 1 | Unknown | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | 65 | 2019-01-25 | 2020-07-22 |
| A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms 18F-AlF-NOTA-octreotide, PET/CT - Neuroendocrine Neoplasm | Phase 1 / Phase 2 | Unknown | Xiangya Hospital of Central South University | 65 | 2018-01-02 | 2018-04-30 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer Carboplatin, Cisplatin, Etoposide - Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 83 | 2015-07-22 | 2026-03-10 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
Neuroendocrine Tumors (11) · Colorectal Neoplasms (3) · Thyroid Neoplasms (3) · Urinary Bladder Neoplasms (3) · Adrenal Gland Neoplasms (2) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Medullary (2) · Carcinoma, Transitional Cell (2) · Cholangiocarcinoma (2) · Hematologic Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2)
Neoplasms (11) · Neoplasms by Histologic Type (11) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms, Nerve Tissue (11) · Neuroectodermal Tumors (11) · Carcinoma (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Adenocarcinoma (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Thoracic Neoplasms (5) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Gastrointestinal Diseases (4)
Magnetic Resonance Spectroscopy (3) · FAPI-46 (2) · Fluorodeoxyglucose F18 (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Al18F-NOTA-octreotide (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Depsipeptides (1) · Etoposide (1) · Lactones (1) · Platinum (1) · Positron Emission Tomography Computed Tomography (1) · Radiation (1) · Radiotherapy (1)
Jonsson Comprehensive Cancer Center (2) · National Cancer Institute (NCI) (2) · Crinetics Pharmaceuticals Inc. (1) · Guangdong Zhongsheng Pharmaceutical Co., Ltd. (1) · Immunome, Inc. (1) · M.D. Anderson Cancer Center (1) · Peking University Cancer Hospital & Institute (1) · Vanderbilt-Ingram Cancer Center (1) · Xiangya Hospital of Central South University (1)
United States (6) · China (3) · Canada (1) · Spain (1)
Jeremie Calais (2) · James Welsh (1) · Jordan Berlin, M.D. (1) · Lowell B Anthony (1) · Roisin M Connolly (1) · Tingting Long, MD,Phd (1)
PMID 20150268, PMID 31605794, PMID 35205614, PMID 39863139
P30CA016672 (1), U01CA062505 (1), U01CA069912 (1), U01CA070095 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186689 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)